Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

219 results about "Methyltransferase" patented technology

Methyltransferases are a large group of enzymes that all methylate their substrates but can be split into several subclasses based on their structural features. The most common class of methyltransferases is class I, all of which contain a Rossman fold for binding S-Adenosyl methionine (SAM). Class II methyltransferases contain a SET domain, which are exemplified by SET domain histone methyltransferases, and class III methyltransferases, which are membrane associated. Methyltransferases can also be grouped as different types utilizing different substrates in methyl transfer reactions. These types include protein methyltransferases, DNA/RNA methyltransferases, natural product methyltransferases, and non-SAM dependent methyltransferases. SAM is the classical methyl donor for methyltrasferases, however, examples of other methyl donors are seen in nature. The general mechanism for methyl transfer is a SN2-like nucleophilic attack where the methionine sulfur serves as the nucleophile that transfers the methyl group to the enzyme substrate. SAM is converted to S-Adenosyl homocysteine (SAH) during this process. The breaking of the SAM-methyl bond and the formation of the substrate-methyl bond happen nearly simultaneously. These enzymatic reactions are found in many pathways and are implicated in genetic diseases, cancer, and metabolic diseases.

TRMT61A and application of TRMT61A inhibitor tetramethylthiuram disulfide in tumor immunotherapy

The invention provides application of TRMT61A and its inhibitor tetramethylthiuram disulfide in tumor immunotherapy, and relates to the technical field of biological medicine, clinical research proves that RNA m1A methyltransferase TRMT61A is highly expressed in tumor tissues and is related to poor prognosis of tumor patients, and can be used as one of tumor therapy targets. Meanwhile, high expression of the TRMT61A is related to poor prognosis of a tumor patient receiving anti-PD-1 immunotherapy, and after anti-PD-1 antibody immunotherapy is carried out on the patient with low TRMT61A expression level in the tumor of the patient, pathological complete relief is easier. Tetramethylthiuram disulfide inhibits TRMT61A, inhibits m1A modification regulation of TRMT61A on PD-L1 mRNA, increases PD-L1 protein expression, and is combined with a PD-1 antibody drug to significantly enhance the immunotherapy effect of the anti-PD-1 immune checkpoint drug in treating malignant tumors.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY (GUANGZHOU SEVERE MATERNAL TREATMENT CENTER GUANGZHOU ROUJI HOSPITAL)

Use of snip1 as a target in the preparation or screening of antitumor drugs

ActiveCN116942816BCompound screeningApoptosis detectionMethyltransferaseNon-histone protein
The application belongs to the technical field of biotechnology and gene therapy, and particularly relates to application of SNIP1 protein as a target in preparation or screening of an antitumor drug. The application finds that the SNIP1 protein is a non-histone substrate of lysine methyltransferase KMT5A, which promotes breast cancer cell growth, invasion and lung metastasis through KMT5A-mediated K301 monomethylation; therefore, the SNIP1 protein can be used as a target for screening of an antitumor drug, and a drug obtained by screening and inhibiting methylation of the K301 site of the SNIP1 protein can be used for antitumor; and the application provides a polypeptide specifically combined with the K301 site of the SNIP1 protein, the polypeptide is combined with the K301 site of the SNIP1 protein, inhibits methylation of the SNIP1 protein, and finally can inhibit tumor growth, proliferation, invasion and metastasis, and can be used as a new targeted antitumor drug.
Owner:SUZHOU QINGRUI BIOTECHNOLOGY CO LTD

Application of caffeic acid-O-methyltransferase in regulating and controlling salt tolerance of rice

PendingCN120796339ABiocidePlant growth regulatorsBiotechnologySalt resistance
The invention discloses an application of caffeic acid-O-methyltransferase in regulation and control of salt tolerance of rice. The overexpressed OsCOMT gene disclosed by the invention can remarkably improve the melatonin content and antioxidant level of rice seedlings, so that the tolerance of plants to salt stress is enhanced, and the plants can maintain normal growth under the condition of salt stress; the deletion of the gene OsCOMT leads to the increase of the sensitivity of seedling-stage rice to salt stress, and exogenous melatonin can recover the salt-sensitive phenotype of a mutant-knocked-out plant and improve the photosynthetic rate of the mutant-knocked-out plant. The OsCOMT gene and the encoding protein thereof have important theoretical and practical significance on research of a plant stress tolerance mechanism and improvement of stress tolerance and related traits of plants, can play an important role in plant stress tolerance gene engineering improvement, and are wide in application prospect.
Owner:YANGZHOU UNIV

Application of CsNOMT gene and sakuranetin in prevention and treatment of tea tree anthracnose

The invention discloses application of a CsNOMT gene and sakuranetin in prevention and treatment of tea tree anthracnose. It is found for the first time that methyltransferase encoded by the tea tree-derived CsNOMT gene can efficiently catalyze naringenin to be converted into sakuranetin, the endogenous phytoalexin level of a tea tree is remarkably improved, and then the disease resistance of the tea tree-derived CsNOMT gene to Colletotrichum carolinae is enhanced. The silence of the CsNOMT gene can reduce the sakuranetin content by 30-40%, resulting in the increase of the scab area; and by overexpressing the gene, the sakuranetin content is increased by 30%, and the scab area is remarkably reduced. In addition, the growth of colletotrichum can be effectively inhibited by exogenously spraying 0.05-0.3 mM of sakuranetin, and the optimal concentration is 0.1-0.3 mM. The invention provides a new strategy for green prevention and control of tea tree anthracnose, and has the characteristics of high efficiency, safety and environmental friendliness.
Owner:ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES

CuCCoAOMT1 gene of Chimonobambusa auriculata, and protein and application of CuCCoAOMT1 gene

The invention discloses a Chimonobambusa chensinensis CuCCoAOMT1 gene as well as a protein and application thereof, belongs to the technical field of plant genetic engineering, and particularly relates to a Chimonobambusa chensinensis caffeoyl-coenzyme A-O-methyltransferase CuCCoAOMT1 gene, and a nucleotide sequence of the CuCCoAOMT1 gene is shown as SEQ ID NO.1. The invention further discloses a preparation method of the CuCCoAOMT1 gene. The invention further discloses application of the CuCCoAOMT1 gene in regulation and control of the drought resistance of gramineous plants. By overexpressing the caffeoyl-coenzyme A-O-methyltransferase CuCCoAOMT1 gene in the rice, the lignin content in the rice can be effectively increased, the thickening of rice cell walls is promoted, the drought resistance of rice plants is improved, and a new gene resource is provided for plant material property improvement gene engineering.
Owner:INT CENT FOR BAMBOO & RATTAN

Serine hydroxymethyltransferase mutant and application thereof in production of L-serine

PendingCN121628869ABacteriaTransferasesEscherichia coliFormaldehyde synthesis
The invention discloses a serine hydroxymethyltransferase mutant and an application thereof in production of L-serin.The serine hydroxymethyltransferase mutant with the specific enzyme activity remarkably improved is obtained by conducting saturated mutation on serine hydroxymethyltransferase from escherichia coli and conducting screening, and the serine hydroxymethyltransferase mutant is applied to synthesis of L-serine. The serine hydroxymethyltransferase disclosed by the invention can be used for effectively improving the efficiency of catalyzing glycine and formaldehyde to synthesize L-serine by using the serine hydroxymethyltransferase, reducing the enzyme dosage, remarkably reducing the production cost and reducing the separation difficulty of downstream products.
Owner:HENAN ZHONGYUAN YUZE BIOTECHNOLOGY CO LTD

Saccharomyces cerevisiae with high yield of salidroside as well as construction method and application of saccharomyces cerevisiae

PendingCN121343793AFungiTransferasesTransketolaseHydroxytyrosol
The invention discloses saccharomyces cerevisiae with high yield of salidroside as well as a construction method and application of the saccharomyces cerevisiae. According to the recombinant saccharomyces cerevisiae, ribulose-5-phosphate isomerase RKI1 and transketolase TKL1 are expressed in host bacteria, so that precursor supply is increased; reverse methyltransferase ARO2 and phenylalanine decarboxylase ARO10 are expressed at the same time, and a tyrosine branch pathway is adjusted; then, UDP-glycosyl transferase of different sources is expressed, and iterative site-specific mutagenesis is carried out on the UDP-glycosyl transferase to enhance conversion of hydroxytyrosol to salidroside; the salidroside production performance of the recombinant strain is verified on the basis of a precursor supply pathway, a tyrosine regulation pathway and key enzyme screening, and the salidroside production capacity of the saccharomyces cerevisiae is further improved.
Owner:NANJING TECH UNIV

Ergothioneine-producing recombinant engineering bacterium as well as construction method and application thereof

The invention discloses an ergothioneine-producing recombinant engineering bacterium as well as a construction method and application thereof, and belongs to the technical field of gene recombination fermentation. The method comprises the following steps: by taking escherichia coli as a starting bacterium, carrying out recombinant expression on a histidine trimethyl inner salt cysteine sulfoxide synthetase egt1 gene, an L-histidine methyltransferase egtD gene, a histidine trimethyl inner salt cysteine sulfoxide lyase egt2 gene, a methionine adenosine transferase metK gene, an adenylate kinase adK gene and an adenine phosphoribose transferase apt gene; on this basis, supply of precursor substances including histidine, cysteine and methionine is further improved through metabolic transformation, the yield of the finally obtained recombinant engineering bacterium for producing ergothioneine reaches 2.54 g / L after 48 h of shake-flask culture, the yield of a 5L fermentation tank reaches 18 g / L after further enlarged culture, the yield of ergothioneine is guaranteed while energy consumption and cost are reduced, and the method is suitable for industrial production. The method is suitable for practical popularization.
Owner:SHANGHAI RECOM BIOTECHNOLOGY CO LTD

Artificial efficient nitrogen fixation system as well as preparation method and application thereof

The invention relates to an artificial efficient nitrogen fixation system and a preparation method and application thereof. The artificial efficient nitrogen fixation system contains recombinant engineering bacteria constructed by an artificial combination module and nitrogen fixation chassis microorganisms; wherein the artificial combination module sequentially comprises a constitutive promoter element Pc and a coding gene of methyltransferase selected from nitrogen-fixing pseudomonas stutzeri A1501 in the direction from upstream to downstream. According to the recombinant engineering bacteria constructed by introducing the artificial combination module into the nitrogen-fixing chassis microorganism, the nitrogenase activity of the nitrogen-fixing chassis microorganism can be remarkably improved, the nitrogen-fixing capacity of the nitrogen-fixing chassis microorganism is remarkably improved, and the recombinant engineering bacteria have a relatively good application prospect in the aspect of promoting plant growth.
Owner:THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI

Extraction method and application of ananas comosus exosome

The present application relates to a kind of anaphalis contorta exosome extraction method and its application.The exosome is obtained by ultra-high speed centrifugation method from fresh anaphalis contorta, particle size is 160-200 nm, Zeta potential is-21.63±1.34 mV, with double membrane structure, mainly containing protein (such as resveratrol O-methyltransferase etc.) and phospholipid, polysaccharide content is only 12.5% of anaphalis contorta fresh medicine, and does not contain traditional active ingredient anaphalis contorta glycoside.Experiments show that anaphalis contorta exosome can be targeted to enrich in colorectal tissue, significantly improve AOM / DSS induced colorectal cancer model mouse tumor microenvironment, reduce tumor number, regulate T cell and macrophage ratio, and relieve pathological damage, better than anaphalis contorta fresh medicine.The mechanism is related to protein component, not polysaccharide or small molecule component.The anaphalis contorta exosome provided in the present application has simple preparation process, high safety, and has significant anti-colorectal cancer application potential.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Methyltransferase mutant and its application in production of icariin

The application provides a methyltransferase mutant and application thereof in production of icariin, and belongs to the technical field of bioengineering. The application solves the problem of low icariin yield in the prior art. The methyltransferase mutant is obtained by mutating any one of the 76th position, the 146th position, the 250th position and the 290th position of the amino acid shown in SEQ ID NO. 2. The methyltransferase mutant is mainly used for efficient methyltransferase and application thereof in synthesis of icariin.
Owner:QINHUANGDAO HUIEN BIOTECHNOLOGY CO LTD

Method for regulating and controlling fish skeletal development through runx2b promoter methylation editing and application thereof

The invention belongs to the technical field of biology, and particularly relates to a construction method of epigenome edited zebrafish, sgRNA of a targeted zebrafish runx2b gene promoter region and application of the sgRNA. The invention provides a construction method of epigenome edited zebrafish, which comprises the step of carrying out methylation editing by using a CRISPR / dCas9-methyltransferase system targeting runx2b gene promoter region, thereby inhibiting runx2b gene expression and reducing intermuscular bone formation. According to the method, the expression level of the runx2b gene is accurately regulated and controlled through an epigenetic editing technology on the premise that a DNA sequence is not changed, and formation of fish intermuscular bones is effectively reduced. The zebra fish F0 treated by the method represents that the runx2b mRNA expression level is obviously reduced, and the intermuscular bones of the eleventh to sixteenth sarcomedo regions of adult F0 generation fish are obviously shorter than those of a control group, and the shortening range reaches 23.3% to 38.8%. Besides, the method provides theoretical basis and technical support for improving fish economic traits by accurately regulating and controlling the expression mode of the key economic trait gene and simultaneously keeping the integrity of genome DNA (Deoxyribose Nucleic Acid).
Owner:SOUTH CHINA NORMAL UNIV

A method for biologically preparing fluorinated phenoxazines and derivatives thereof and applications thereof

This invention discloses a method for the biosynthesis and application of fluorinated phenazine and its derivatives, belonging to the field of bioengineering technology. The invention aims to provide a method for synthesizing fluorinated phenazine and its derivatives. Specifically, it provides an in vitro enzyme cascade catalytic reaction method for synthesizing fluorinated phenazine and its derivatives, in which halogenated methyltransferase HMT1 and O-methyltransferase LaphzM, or halogenated methyltransferase HMT1 and N-methyltransferase PhzM, are added to a reaction buffer containing 1-hydroxyphenazine and its derivatives to obtain fluorinated phenazine and its derivatives. The enzyme concentrations of halogenated methyltransferase HMT1 and O-methyltransferase LaphzM are 2:1; the enzyme concentrations of halogenated methyltransferase HMT1 and N-methyltransferase PhzM are 2:1. This establishes a pathway for the synthesis of fluorinated phenazine from 1-hydroxyphenazine and its derivatives, providing a new approach for the biosynthesis of fluorinated phenazine.
Owner:SHANDONG UNIV OF TECH

Connecting peptide and application thereof in promoting compound glucose methylation modification

The invention discloses a connecting peptide and application thereof in promoting compound glucose methylation modification. A glycosyl transferase-methyltransferase fusion protein gene and genes LtLasS1 and LtLasS2 coded by benzenediol lactone synthetase, which are connected in series by connecting peptides, are co-expressed, and liquid phase and mass spectrometry of a fermentation product are carried out to determine that the fusion protein can realize glucose methylation modification by hydroquinone lactone. Wherein the conversion efficiency of the fusion protein hydroquinone lactone using the DL-4 connecting peptide is the highest, and the relative conversion rate is 65.54 + / -3.75%. Besides, by feeding a substrate kaempferol and testing the glucose methylation conversion efficiency of the artificial fusion protein constructed by the connecting peptide, the conversion efficiency of the fusion protein using the DL-4 connecting peptide to the substrate is 6 times of the conversion efficiency of the fusion protein using a single glycosyl transferase and a single methyltransferase to the substrate, and the relative conversion rate is increased to 60.12 + / -4.79%.
Owner:YANGZHOU UNIV +1

Methods for quantitative monitoring of mRNA capping efficiency

This invention relates to a method for quantifying mRNA capping efficiency, the method comprising mixing a sample, an enzyme mixture, and an isotope standard solution in a buffer solution to produce an incubation mixture, the enzyme mixture comprising a nonspecific single-stranded nuclease and an acid phosphatase, and the isotope standard comprising isotopically labeled m7G and isotopically labeled 2'-O-methylated nucleoside; incubating the mixture; and analyzing the mixture using liquid chromatography-mass spectrometry to determine at least one of capping efficiency and 2-O-methyltransferase efficiency.
Owner:THERMO FINNIGAN LLC

A methyltransferase cicomt10 mutant, preparation method, biomaterial and application

ActiveCN120591230BBacteriaTransferasesThreonineEriodictyol
The present application relates to a kind of methyltransferase CicOMT10 mutant, preparation method, biological material and application.The methyltransferase mutant is mutated with the amino acid sequence such as SEQ ID NO:1 CicOMT10 enzyme, and the mutation includes: the asparagine of 179th is mutated to alanine;And / or, the threonine of 316th is mutated to alanine.The methyltransferase mutant of the present application can efficiently convert eriodictyol into hesperetin.
Owner:FOSHAN GOLDEN HEALTH TECH CO LTD +1

Genetically engineered bacterium for synthesizing melatonin and application of genetically engineered bacterium

The invention relates to the field of genetic engineering and fermentation engineering, and discloses a genetically engineered bacterium for producing melatonin and application of the genetically engineered bacterium in fermentation production of melatonin. According to the invention, genes of mtrA, PTPS, SPR, PCD and DHPR of related enzymes synthesized by coding 2-amino-6-(1, 2-dihydroxypropyl)-5, 6, 7, 8-tetrahydro-4 (1H)-pterin diketone and genes of L-2-amino-3 (beta-indole) propionic acid monooxygenase, oxymethyltransferase, N-acetyltransferase and decarboxylase are co-expressed on the genetically engineered bacterium, so that the gene engineering bacterium is obtained. The strain can be used for fermentation production of melatonin, and experiments show that the yield of the strain can reach 6480 mg / L.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Chromatin modification detection kit and detection method for regulating ATIC expression by PRMT8

The invention belongs to the technical field of kit detection, discloses a chromatin modification detection kit for regulating ATIC expression through PRMT8, and discovers the specific expression and cancer promotion function of arginine methyltransferase PRMT8 and purine de novo synthesis key enzyme ATIC in triple negative breast cancer for the first time. The specific biological effect of the PRMT8 in the triple negative breast cancer is researched for the first time, and the PRMT8 promotes ATIC transcriptional activation by mediating phosphorylation of an ATIC promoter region H4R3me2a and an effect protein TDRD3 of the PRMT8. The important function of arginine methyltransferase PRMT8 in a tumor purine metabolic pathway is found by gradually exploring the transcriptional activation process of purine metabolic rate-limiting enzyme ATIC, the post-translational modification function of histone is associated with the activation of the breast cancer purine metabolic pathway, and a new theoretical basis is provided for treating breast cancer by targeting PRMT8.
Owner:HARBIN MEDICAL UNIVERSITY

Method for producing Labyrinthula microorganisms and sterol esters

PendingJP2026115641AMicroorganismSterol ester
The object of this invention is to provide Labyrinthula microorganisms that have high sterol ester production capacity. [Solution] A Labyrinthull microorganism modified to have reduced or lost activity of sterol 24-C-methyltransferase (SMT1) compared to an unmodified strain, wherein the Labyrinthull microorganism is modified to express a modified diacylglycerol acyltransferase 2C (modified DGAT2C) gene, and the modified diacylglycerol acyltransferase 2C (modified DGAT2C) is modified to have a defect in presumed transmembrane regions 1 to 8 of the presumed transmembrane regions 1 to 12 in diacylglycerol acyltransferase 2C (DGAT2C).
Owner:KYUSHU UNIV +1

Composition for promoting expression of glycine-n-methyltransferase

The invention provides a composition containing a white peony root extract, a Chinese magnoliavine fruit extract, a pomegranate extract and a ginseng extract. The composition or the nutritional supplement and the pharmaceutical composition containing the composition can obviously promote the expression of the individual glycine-N-methyltransferase, so that the composition can be applied to nutritional supplement or pharmaceutical products for resisting aging, fatty liver or liver cancer and the like.
Owner:THE ONE BIOPHARMACEUTICAL CO LTD

Application of GmMETTL1 and / or GmWDR4 in regulation and control of plant drought resistance

The invention belongs to the technical field of plant stress resistance molecular biology and genetic engineering, and particularly relates to application of GmMETTL1 and / or GmWDR4 in regulation and control of plant drought resistance, the base sequence of the GmMETTL1 is as shown in SEQ ID NO.1, and the base sequence of the GmWDR4 is as shown in SEQ ID NO.2. The invention also relates to application of the GmMETTL1 and / or GmWDR4 in regulation and control of plant drought resistance. The invention discloses application of GmMETTL1 and GmWDR4 in synergistically promoting leaf water retention and stomatal regulation of soybeans in a drought environment, finding that the GmMETTL1 and GmWDR4 have a protein interaction relationship in the soybeans for the first time, and filling the blank of synergistically regulating and controlling a molecular mechanism that the soybeans respond to drought stress by GmMETTL1 methyltransferase and the interaction protein GmWDR4 of the GmMETTL1 methyltransferase. The method has important significance on genetic engineering research and germplasm resource creation and utilization of the drought-resistant soybeans.
Owner:JILIN AGRICULTURAL UNIV

Preparation method of irisflorentin

PendingCN121801985ABacteriaTransferasesS-Adenosyl-l-methionineBelamcanda chinensis
The invention relates to a method for preparing irisflorentin by utilizing belamcandin, and belongs to the technical field of biology. The method comprises the following steps: carrying out C-5 site and C-3'site methylation reaction by taking white belamcandin as a substrate, taking belamcanda methyl transferase gene BcOMT03 gene encoding protein and belamcanda methyl transferase BcOMT33 gene encoding protein as catalysts and taking S-adenosine-methionine as a methyl donor to generate a corresponding glycosylation product. According to the invention, the functions of the two methyltransferase genes BcOMT03 and BcOMT33 in the blackberry lily are identified and verified for the first time, the effect of the two methyltransferase genes BcOMT03 and BcOMT33 in catalyzing the ibullamcandin to produce the irisflorentin is defined, and the blank of research on the biosynthetic pathway of the characteristic component irisflorentin of the blackberry lily is filled up; important information is provided for research on a biosynthesis mechanism of active ingredients of medicinal plants.
Owner:YUNNAN AGRICULTURAL UNIVERSITY

Astragalus mongholicus calycosin methyltransferase protein AmOMT1, coding gene, primer group and application of astragalus mongholicus calycosin methyltransferase protein AmOMT1

The invention provides an astragalus membranaceus calycosin-7-methyltransferase protein AmOMT1, a coding gene, a primer group and application of the astragalus membranaceus calycosin-7-methyltransferase protein AmOMT1, and belongs to the technical field of biology. The amino acid sequence of the astragalus membranaceus calycosin-7-methyltransferase protein AmOMT1 is as shown in SEQ ID No. 1 (sequence identifier number 1). According to the present invention, based on the radix astragali seu hedysari genome and the second-generation transcriptome data, the transmethylase AmOMT1 having 4 'and 7-site methylation functions on 3', 4 ', 7-trihydroxy isoflavone simultaneously is found and identified by using the reverse genetics method, and the experiment results show that the AmOMT1 can catalyze the methylation of the 3', 4 ', 7-trihydroxy isoflavone to generate calycosin and 3', 4 '-dihydroxy-7-isoflavone, and the transmethylase AmOMT1 can catalyze the methylation of the 3', 4 ', 7-trihydroxy isoflavone can catalyze the methylation of the 3', 4 ', 7-trihydroxy isoflavone to generate the 3', 4 '-dihydroxy-7-isoflavone.
Owner:INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES

Methods for generating hematopoietic stem cells

In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and / or GTPase IMAP Family Member 6 (Gimap6) in the HE and / or endothelial cells under conditions sufficient for stimulating formation of HSCs.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Guanidinoacetic acid N-methyltransferase mutant and application thereof in synthesis of creatine

PendingCN121182771ABacteriaTransferasesS-Adenosyl-l-methionineMethyltransferase
The invention discloses a guanidinoacetic acid N-methyltransferase mutant and application of the guanidinoacetic acid N-methyltransferase mutant in synthesis of creatine, and belongs to the technical field of bioengineering. The invention provides a method for preparing creatine by utilizing a guanidinoacetic acid N-methyltransferase mutant (Y134I / N170H) and catalyzing guanidinoacetic acid and S-adenosylmethionine in a whole-cell form. The genetically engineered bacterium for expressing the guanidinoacetic acid N-methyltransferase mutant is fermented for 24 hours under the conditions that the whole cell amount is 0.2 g, the pH value is 7.5, the reaction temperature is 37 DEG C, the concentration of guanidinoacetic acid is 80 mM, and the concentration of S-adenosylmethionine is 100 mM, the creatine yield is 7.34 g / L, and the molar yield is 69.96%. According to the method disclosed by the invention, the production cycle is shortened, the yield of creatine is increased, and the industrial process of producing creatine by an enzyme conversion method is accelerated.
Owner:SHANDONG KAIMIS NEW MATERIAL TECH CO LTD +1

A gain-of-function mutation in poxvirus encoded 2'o-methyltransferase: enhancing stability and translational efficiency of viral mRNA

The present invention is related to method of preparing a gain-of-function mutation in poxvirus, like buffalopox virus (BPXV) by long-term propagating it in the presence of methyltransferase inhibitor like 3-Deazaneplanocin A (DZNep), which results in generation of viral 2'O-MTAse (VP39) mutant with a single point mutation (M236I). The resultant mutant has the following characteristics: (a) M236I mutation of 2'O-MTAse increases the cap-1 markings on viral mRNA; (b) The 2'O-MTAse mutant virus had hyperactive 2'O-MTAse and exhibited enhanced stability and translational efficiency of its mRNA; (c) The capping (cap1) performed by the mutant viral 2'O-MTAse (VP39) results in higher viral protein production, as compared to the wild type VP39 and (d) Mutant virus replicated at higher viral titer than the wild-type virus.
Owner:ICAR-NAT RES CENT ON EQUINES

Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor

PCT designated stageWO2025237957A1Organic active ingredientsAntineoplastic agentsHormone dependencePharmaceutical drug
The invention relates to methods and pharmaceutical composition for the treatment of estrogen-dependent cancers, particularly estrogen receptor-related cancers such as estrogen receptor-positive (ER+) cancers, like ER+ breast cancer (ER+BC). The invention relates to the combined use of an inhibitor of the methyltransferase-like protein 3 (METTL3) and an inhibitor of the nuclear DNA topoisomerase I (TOP1) for the treatment of estrogen-dependent cancers, particularly estrogen receptor-related cancers such as ER+ cancers. The inhibition of METTL3 increases the sensitivity of ER + breast cancer cells to Topoisomerase-1 inhibitor.
Owner:INSTITUT CURIE +2

Polyheterocyclic compounds as mettl3 inhibitors

METTL3 (N6 Adenosine Methyltransferase 70kDa Subunit) To provide an inhibitor of enzyme activity.SOLUTION: For example, N - ({2 - [(4, 4-dimethylpiperidin-l-yl) methyl] - 1H - indol-6-yl} methyl) - 4-oxo - 4H - pyrido [l, 2-a] pyrimidine-2-carboxamide is shown to have the following structure. The invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions containing them and to their use in the treatment of proliferative disorders such as cancers and auto-immune diseases and other diseases or conditions in which METTL3 activity is implicated.SELECTED DRAWING: None
Owner:STORM THERAPEUTICS LIMITED

A monkeypox virus n7-methyltransferase inhibitor high-throughput screening method based on fluorescence polarization technology and application

This invention discloses a high-throughput screening method for monkeypox virus (MPXV) N7-methyltransferase (N7-MTase) inhibitors based on fluorescence polarization technology and its application. This method uses MPXV E1... CTD Using the / E12 protein complex as a target, and leveraging the specific binding characteristic of the fluorescent probe FL-NAH to the target catalytic center, small molecule inhibitors that competitively bind to the SAM binding site are screened by monitoring changes in fluorescence polarization signals. This invention yielded a series of candidate compounds with significant inhibitory activity. Experiments demonstrated that these inhibitors exhibit strong inhibitory effects on MPXV N7-MTase, with a biochemical IC50 level of [missing information]. 50 Preferably, the concentration can reach 4.65 μM; at the cellular level, the compound exhibits a clear attenuation effect against poxviruses, with an EC50 value of [missing value]. 50 The range is up to 46.75 μM, and it has low cytotoxicity (CC). 50 >200 μM).
Owner:ZHEJIANG UNIV